Background Findings from family and twin studies suggest that genetic contributions to psychiatric disorders do not in all cases map to present diagnostic categories. We aimed to identify specifi c variants underlying genetic eff ects shared between the fi ve disorders in the Psychiatric Genomics Consortium: autism spectrum disorder, attention defi cit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia.
Introduction
Psychiatric nosology arose in central Europe towards the end of the 19th century, in particular with Kraepelin's foundational distinction between dementia praecox (schizophrenia) and manic depressive insanity. 1 The distinction between bipolar illness and unipolar (major) depression was fi rst proposed in the late 1950s and became increasingly widely accepted. The major syndromes-especially schizophrenia, bipolar disorder, and major depression-were diff erentiated on the basis of their symptom patterns and course of illness. At the same time, clinical features such as psychosis, mood dysregulation, and cognitive impairments were known to transcend diagnostic categories. Doubt remains about the boundaries between the syndromes and the degree to which they signify entirely distinct entities, disorders that have overlapping foundations, or diff erent variants of one underlying disease. Such debates have inten si fi ed with syndromes described subsequently, including autism spectrum disorders and attention defi cit-hyperactivity disorder.
The pathogenic mechanisms of psychiatric disorders are largely unknown, so diagnostic boundaries are diffi cult to defi ne. Genetic risk factors are important in the causation of all major psychiatric disorders, 2 and genetic strategies are widely used to assess potential overlaps. The imminent revision of psychiatric classifications in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD) has reinvigorated debate about the validity of diagnostic boundaries. With increasing availability of large genome-wide genotype data for several psychiatric disorders, shared cause can now be examined at a molecular level.
We formed the Psychiatric Genomics Consortium (PGC) in 2007, to undertake meta-analyses of genomewide association studies (GWAS) for psychiatric disorders and, so far, the consortium has incorporated GWAS data from more than 19 countries for schizophrenia, bipolar disorder, major depressive disorder, attention defi cit-hyperactivity disorder, and autism spectrum disorders. Previous research has suggested varying degrees of overlap in familial and genetic liability for pairs of these disorders. For example, some fi ndings 3, 4 from family and twin studies support diagnostic boundaries between schizophrenia and bipolar disorder and bipolar disorder and major depressive disorder, but also suggest correlations in familial and genetic liabili ties. 3, 5 Several molecular variants confer risk of both schizophrenia and bipolar disorder. [6] [7] [8] Autism was once known as childhood schizophrenia and the two disorders were not clearly diff erentiated until the 1970s. Findings from the past few years have emphasised phenotypic and genetic overlap between autism spec trum disorders and schizophrenia, 9, 10 including identifi cation of copy number variants conferring risk of both. 11 Findings from family, twin, and molecular studies [12] [13] [14] [15] suggest some genetic overlap between autism spectrum disorder and attention defi cit-hyperactivity disorder.
In this fi rst report from the PGC Cross-Disorder Group, we analyse data on genome-wide single-nucleotide polymorphism (SNP) for the fi ve PGC dis orders to answer two questions. First, what information emerges when all fi ve disorders are examined in one GWAS? When risk is correlated across disorders, pooled analyses will be better powered than individual-disorder analyses to detect risk loci. Second, what are the cross-disorder eff ects of variants already identifi ed as being associated with a specifi c psychiatric disorder in previous PGC analyses? We aimed to examine the genetic relation between the fi ve psychiatric disorders with the expectation that fi ndings will ultimately inform psychiatric nosology, identify potential neurobiological mechanisms predisposing to specifi c clinical presentations, and generate new models for prevention and treatment.
Methods

Samples and genotypes
The sample for these analyses consisted of cases, controls, and family-based samples assembled for previous genome-wide PGC mega-analyses of individuallevel data. 6, 7, 16, 17 Cases and controls were not related. For the family-based samples, we matched alleles transmitted to aff ected off spring (trio cases) with untransmitted alleles (pseudocontrols). We estimated the identity-bydescent relation for all pairs of individuals to identify any duplicate individuals in the component datasets. When duplicates were detected, one member of each set was retained. We then randomly allocated these individuals, with a random number generator, to a disorder casecontrol dataset. Sample sizes diff er from previous reports because of this allocation of overlapping individuals. All patients were of European ancestory and met criteria from the DSM third edition revised or fourth edition for the primary disorder of interest.
To ensure comparability between samples, raw genotype and phenotype data for each study were uploaded to a central server and processed through the same quality control, imputation, and analysis process (appendix). 6, 7 We analysed imputed SNP dosages from 1 250 922 autosomal SNPs.
Statistical analysis
In the primary analysis, we combined eff ects of each disease analysis by a meta-analytic approach that applied a weighted Z-score, 18 in which weights equalled the inverse of the regression coeffi cient's standard error. This strategy assumed a fi xed-eff ects model, with weights indicating the sample size of the disease-specifi c studies. In a second analytical approach, we did a fi ve-degree-offreedom test by summing the χ² values for each individual disease meta-analysis. Unlike our primary analysis, this model did not assume that all diseases had the same direction of eff ect and could detect allelic eff ects that increase risk for some diseases and decrease risk for others. The appendix describes statistical methods and results, including the handling of trios and population stratifi cation. We also examined loci that previously achieved genome-wide signifi cance in PGC metaanalyses of schizophrenia and bipolar disorder. 6, 7 To characterise the specifi city of the allelic eff ects for our main fi ndings, we examined the association evidence in three ways: we generated forest plots of the disorder beta coeffi cients with 95% CIs; we calculated a heterogeneity p value for the disorder-specifi c eff ects contributing to the overall statistics for meta-analytic association; and we undertook a multinomial logistic regression procedure with model selection 19 for each main SNP for all fi ve disorders to assess the pattern of phenotypic eff ects (appendix pp [8] [9] [10] [11] . To compare the fi t of various models of genotype-phenotype associations, we applied established goodness-of-fi t metrics (the Bayesian information criteria and the Akaike information criteria). We report the best-fi tting model by Bayesian criteria and show results of both metrics for a range of models (appendix pp 38-45, 51-61).
To examine shared polygenic risk at an aggregate level between pairs of diagnoses, we used risk-score profi ling as previously described. 8 For each pair, we selected one disorder as a discovery dataset and the other as a target dataset and calculated the proportion of variance in the target set explained by risk scores from the discovery set with a range of statistical cutoff s for SNP inclusion in the score (appendix p 13). To assess the role of specifi c biological systems in the pathogenesis of the fi ve disorders, we did pathway and eQTL analyses. Pathway analysis was by interval-based enrichment analysis (INRICH) for the full dataset consisting of linkage disequilibrium segments containing signals with association p<10 -³ in the primary meta-analysis. INRICH accounts for poten tial genomic confounding factors, such as variable gene and pathway sizes, SNP density, linkage disequilibrium, and physical clustering of biologically related genes (appendix pp [14] [15] [16] . We did eQTL enrichment analysis 20 to assess whether SNPs associated with fi ve psychiatric disorders were enriched for regulatory SNPs in post-mortem brain tissue harvard.edu/inrich samples compared with those with no association. 21, 22 To assess the specifi city of this fi nding, we also examined eQTL datasets from three non-brain-tissue types: liver, 23 skin, 24 and lymphoblastoid cell lines 25 (appendix pp [17] [18] [19] [20] [21] .
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data and had fi nal responsibility for the decision to submit for publication.
Results
The fi nal dataset consisted of 33 332 cases and 27 888 controls (including pseudocontrols formed from nontransmitted alleles) distributed among the fi ve disorder groups: autism spectrum disorders (4788 trio cases, 4788 trio pseudocontrols, 161 cases, 526 controls), attention defi cit-hyperactivity disorder (1947 trio cases, 1947 trio pseudocontrols, 840 cases, 688 controls), bipolar disorder (6990 cases, 4820 con trols), major depressive disorder (9227 cases, 7383 con trols), and schizophrenia (9379 cases, 7736 controls). The results of the primary fi xed-eff ects meta-analysis for all fi ve disorders, incorp orating seven multidimensional scaling components as covariates, yielded a genomic control value of λ=1·167. The λ 1000 (λ rescaled to a sample of 1000 cases and 1000 controls) was 1·005 (appendix p 22). In view of evidence for substantial polygenic contributions to common psy chiatric disorders, this estimate probably shows the aggregate small eff ect of a large number of risk variants, although a moderate degree of population stratifi cation or technical bias cannot be excluded. Figure 1 shows the Manhattan plot of the primary results. Four independent regions contained SNPs Chromosome
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Nearest gene Alleles Frequency † Imputation quality score (INFO) p value OR (95% CI) ‡ Heterogeneity p value
Best-fi t model (BIC) §
Five disorder ¶ Most strongly associated single-nucleotide polymorphisms (SNP) in associated region after clumping-ie, grouping SNPs within 250 kb of the index SNP that have r²>0·2 with the index SNP as implemented in PLINK. OR=odds ratio. BIC=Bayesian information criteria. BPD=bipolar disorder. *Detected with University of California Santa Cruz Genome Browser (version hg18). †Risk allele frequency in controls. ‡Estimated OR from multinomial logistic regression used in the modelling analysis. §Best-fi t multinomial logistic model by BIC criteria; appendix pp 38-45 provide a comparison of BIC and Akaike information criteria across models. ¶Best-fi t model supports an eff ect on all fi ve disorders. CNNM2. We also recorded genome-wide signifi cant association within CACNA1C, and fi nally detected signifi cant association to a second locus on chromosome 10 in an intron of CACNB2 (table 1) . We undertook conditional analyses to assess evidence for multirisk loci in a region. In these analyses, we included the most strongly associated or peak SNP plus any SNPs within 1·5 Mb of the peak SNP with association p values less than 10 -⁴ and r² less than 0·2 with the peak SNP based on HapMap 3 CEU data. For the chromosome 3p21 region, and regions CACNA1C and CACNB2, no additional independent association signals were de tected. For the chromosome 10q24 region, an additional SNP (rs11191732), about 600 kb from the peak SNP, showed association after conditioning on the peak SNP (rs11191454) with a p value of 6·60×10 -⁶ before conditioning and 3·88×10 -⁵ after conditioning. Several loci previously implicated in PGC analyses of schizophrenia and bipolar disorder 6, 7 showed evidence for association in the cross-disorder analysis, despite not exceeding the cutoff for genome-wide signifi cance (appendix pp [23] [24] . These loci include one near MIR137, TCF4, the MHC region on chromosome 6, and SYNE1 (appendix pp [23] [24] . The fi ve-degree-of-freedom χ² test did not iden tify any additional genome-wide signifi cant SNPs with eff ects in the opposite direction among the fi ve disorders (appendix pp [36] [37] .
Forest plots for genome-wide signifi cant SNPs showed the same direction of eff ect for most or all of the fi ve disorders (fi gure 2). For three of the four associated regions, the meta-analysis heterogeneity p value was not signifi cant and a model in which all fi ve disorders contributed provided the best fi t (table 1). The exception was rs1024582, for which the heterogeneity p value was signifi cant and the best-fi t model supported an eff ect limited to bipolar disorder and schizophrenia (table 1) . Appendix pp 38-45 shows the profi le of the Bayesian and Akaike information criteria measures for each SNP for a range of models. We examined the association between the fi ve disorders of four SNPs showing genome-wide signifi cant association with bipolar disorder (table 2) and ten associated with schizophrenia (table 2). 6, 7 Appendix pp 46-61 show forest plots and model-fi tting results by disorder. The best-fi tting model for seven of the 14 risk SNPs suggested disorder-specifi c eff ects for either bipolar disorder (three SNPs) or schizophrenia (four SNPs), whereas the rest were consistent with more pleiotropic models (table 2) . Figure 3 shows the proportion of variance explained in target sets (Nagelkerke's pseudo R² from logistic regression) by risk scores from the discovery sets. We noted highly signifi cant overlap of polygenic risk between all three adult disorders (bipolar disorder, major depressive disorder, and schizophrenia), with the strongest eff ects noted for bipolar disorder and schizo phrenia (fi gure 3). Overlap was reduced but still sig nifi cant between aggregate genetic risk for autism spectrum disorder with schizophrenia (minimum p<10 -⁴) and bipolar disorder (p<0·05; fi gure 3). No consistently signifi cant polygenic overlap was detected between major depressive disorder and autism spectrum disorder or between attention defi cit-hyperactivity disorder and any other disorder. provide a comparison of BIC and Akaike information criteria across models). §The BIC for the best and second best models do not diff er signifi cantly (ie, greater than 2 as previously suggested 26 ). ¶rs4765914 is a proxy SNP for rs4765913 based on linkage disequilibrium (481 base pairs away, r²=0·874).
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Table 2: Modelling analysis results for single-nucleotide polymorphisms (SNP) showing genome-wide signifi cant association in previous genome-wide association studies from the Psychiatric Genome-Wide Association Study Consortium
Appendix p 63 shows additional polygene analyses combining subsets of disorders into discovery sets. After correction for multiple testing (appendix pp 14-16), we noted signifi cant enrichment for a set of calcium channel activity genes associated with catalysis of facilitated diff usion of cal cium ions through a trans membrane calcium channel (appendix p 64). With a cutoff of p<10 -³, 20 of 67 gene regions in this set were associated in the fi vedisorder meta-analysis, including voltage-gated calciumchan nel subunits CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNA2D2, CACNA2D4, and CACNB2 (appendix pp 65-66). Because calcium-channel genes (mainly CACNA1C) have previously been associated with bipolar disorder, we repeated the pathway analysis with exclusion of the datasets for bipolar disorder and confi rmed that enrichment was not dependent on cases with this disorder (data not shown). Appendix pp 69-70 depict functional associations between these calcium-channel activity genes on the basis of various lines of evidence. Table 3 summarises results of the eQTL enrichment analysis for SNPs selected at varying p-value cutoff s from the primary cross-disorder meta-analysis. We noted a signifi cantly greater proportion of brain eQTL markers in cross-disorder-selected SNPs than expected in view of their distribution of frequencies for minor alleles. We consistently noted this enrichment for two of the three studies of post-mortem brain eQTL for various p-value cutoff s (table 3) and when analyses included all SNPs or were restricted to retain only one SNP tagging (r²>0·8) an associated region. No consistent enrichment was noted in the three non-brain-tissue datasets (table 3) .
Discussion
This study is the largest genome-wide analysis of psychiatric illness so far and the fi rst to provide evidence that specifi c SNPs are signifi cantly associated with a range of childhood-onset and adult-onset psychiatric disorders. For the fi ve disorders studied, SNPs at four loci-regions on chromosomes 3p21 and 10q24, and SNPs in two L-type voltage-gated calcium-channel subunits, CACNA1C and CACNB2-exceeded the cutoff for genome-wide signifi cance in the primary analysis. The strongest signal was within a region on chromosome 3p21.1. Aggregate polygenic risk scores for a broad set of common variants showed cross-disorder eff ects for all the adult-onset disorders (bipolar and major depressive disorder, and schizophrenia) and nominally between autism spectrum disorders and both bipolar disorder and schizophrenia.
In view of extensive linkage disequilibrium in the 3p21.1 region, encompassing more than 30 genes, we could not identify the causal locus. Genome-wide signifi cant association to the 3p21.1 region has previously been reported in GWAS of samples overlapping with ours at rs1042779 (12 kb from our peak SNP) for bipolar disorder, 28 rs736408 (2 kb) for a combined bipolar disorder and schizophrenia phenotype, 7 and rs2251219 (248 kb) for a combined major depressive and bipolar disorder phenotype. 29 Reanalysis of this last combined dataset suggested that the signal was largely attributable to the group with bipolar disorder. 30 Furthermore, the association evidence for our peak chromosome 3 SNP rs2535629 was genome-wide signifi cant in a joint analysis of bipolar disorder and schizophrenia samples done by the PGC schizophrenia group (p=7·8×10 -⁹). 6 Our model-selection analysis was designed to characterise the range of phenotypic eff ects for loci that showed signifi cant association; however, the statistical evidence and eff ect size for each contributing disorder can vary. Although the best-fi t model for the chromosome 
Cross-disorder risk SNPs were defi ned as those meeting the p-value cutoff s shown in the left column in the primary meta-analysis of fi ve disorders, and residing within 1 M bases from human reference hg18 genes. LPL=lymphoblastoid cell lines. 3p21 region included all fi ve disorders, interpretation of these results is complicated by evidence from a PGC GWAS mega-analysis of major depressive disorder. 17 In the discovery phase of that analysis, which consisted of 9240 major depressive disorder cases and 9519 controls many of whom overlap with samples reported here, the smallest association p value for this region (rs2535629) was 0·00013. However, no association was noted in a replication dataset of 6783 cases and 50 695 controls (p=0·70) for that disorder, and the combined discovery and replication phase p value was 0·0031. Thus, any association between this region and major depressive disorder is unclear. Two of the four genome-wide signifi cant signals in our analysis localise to introns of brain-expressed genes encoding L-type voltage-gated calcium-channel subunits (CACNA1C and CACNB2). Previous disorder-specifi c GWAS, overlapping with the samples included here, identifi ed CACNA1C as a susceptibility gene for bipolar disorder, 7,31 schizophrenia, 6 and major depressive disorder. 32 Gain-of-function mutations in CACNA1C cause Timothy syndrome, a developmental disorder in which the phenotypic range includes autism. 33 Consistent with a pleiotropic role, neuroimaging studies have documented eff ects of CACNA1C variants on a range of structural and functional brain phenotypes, including circuitry involved in emotion processing, 34 executive function, 34 attention, 35 and memory. 36 CACNB2 encodes an auxiliary voltage-gated calcium-channel subunit that interacts with L-type calcium-channel subunits (in cluding CACNA1C, CACNA1D, and CACNA1S) to promote their traffi cking to the plasma membrane, increase their function, and regulate their modulation by other signalling proteins and molecules. 37 Although previous PGC analyses (schizophrenia and bipolar disorder) did not identify CACNB2 as a risk gene, a variant in CACNB2 (52 kb from our peak SNP) was one of the main signals in an independent GWAS of bipolar disorder in Han Chinese individuals. 19 The pleiotropic eff ects of voltage-gated calcium channels on childhood-onset and adult-onset psychiatric disorders are underscored by pathway analysis in which calcium-channel activity genes, including our main two L-type subunit genes, showed signifi cant enrichment in the fi ve disorder dataset. The PGC analysis of bipolar disorder reported enrichment of a pathway including CACNA1C and CACNA1D; importantly, however, we detected enrichment of these genes after exclusion of the bipolar disorder dataset. Thus, our results suggest that voltage-gated calcium signalling, and, more broadly, calcium-channel activity, could be an important biological process in psychiatric disorders. A fourth region associated with cross-disorder eff ects was on chromosome 10, encompassing several genes with the peak signal in an intron of AS3MT. Loci previously associated with schizophrenia and bipolar disorder 6,7 had varying evidence of association for the other major psychiatric disorders. For example, a locus previously strongly associated with schizophrenia, encompassing MIR137 and DPYD on chromosome 1, showed similar evidence of association with autism spectrum disorders; this fi nding is consistent with reports that autism spectrum disorders are related to microdeletions of this region. 38, 39 Accumulating evidence, including that from clinical, epidemiological, and molecular genetic studies, suggests that some genetic risk factors are shared between neuropsychiatric disorders. Genome-wide studies have identifi ed rare copy-number variants that confer risk of several neuropsychiatric disorders including autism, attention defi cit-hyperactivity disorder, epilepsy, intellectual disability, and schizophrenia. 39 Our analyses of 14 SNPs previously identifi ed as being genome-wide signifi cantly associated with schizophrenia and bipolar disorder suggest that some loci identifi ed in studies of individual disorders have broader phenotypic eff ects.
Table 3: Expression quantitative trait loci enrichment analysis for single-nucleotide polymorphisms (SNPs) from primary meta-analysis by p-value cutoff s
Panel: Research in context
Systematic review
Psychiatric diagnoses are presently defi ned as descriptive syndromes on the basis of a consensus of experts. The aetiological relations among these disorders are a topic of active debate in view of the imminent revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classifi cation of Diseases (ICD-11). Many family and twin studies [3] [4] [5] [12] [13] [14] have documented familial and heritable overlap between subsets of the fi ve disorders we examined. Genetic association studies [6] [7] [8] 32, 43, 44 including samples smaller than those reported here have provided some support for these associations at a molecular level. We searched the National Human Genome Research Institute (NHGRI) GWAS catalogue as of September, 2012, to identify all previous reports of genome-wide signifi cant association for any of the fi ve disorders. For each signifi cant gene or gene region identifi ed, we then searched Medline for reports of at least nominally signifi cant association (p<0·001) with at least one of the remaining four disorders. Several such loci have been reported including CACNA1C (for schizophrenia, bipolar disorder, and major depressive disorder), ZNF804A, ANK3, DGKH, and the 3p21.1 and NCAN (schizophrenia and bipolar disorder). 32, [45] [46] [47] [48] [49] [50] Furthermore, polygene score analyses have shown signifi cant overlap between schizophrenia and bipolar disorder and between bipolar disorder and major depressive disorder. Finally, several rare copy-number variations associated with autism spectrum disorders have been detected in schizophrenia, attention-defi cit hyperactivity disorder, bipolar disorder, and recurrent major depressive disorder. 39 However, no previous studies have examined cross-disorder eff ects encompassing all fi ve of the disorders examined here.
Interpretation
This analysis provides the fi rst genome-wide evidence that individual and aggregate molecular genetic risk factors are shared between fi ve childhood-onset or adult-onset psychiatric disorders that are treated as distinct categories in clinical practice. As such, our fi ndings are relevant to the goal of moving beyond descriptive syndromes in psychiatry and towards a nosology informed by disease cause. The fi nding that genetic variants have cross-disorder eff ects is an empirical step towards helping clinicians understand the common co-occurrence of clinical phenotypes in individual patients. Our results implicate a specifi c biological pathway-voltage-gated calcium-channel signalling-as a contributor to the pathogenesis of several psychiatric disorders, and support the potential of this pathway as a therapeutic target for psychiatric disease. These results add to literature in several specialties (including autoimmune and metabolic diseases) that have begun to document widespread pleiotropy of genetic risk factors across traditional diagnostic boundaries.
For the NHGRI GWAS catalogue see http://www.genome. gov/26525384
Our results suggest a diversity of fi ndings, with some SNPs showing diagnostic specifi city and others pleiotropic eff ects on two or more of the fi ve disorders.
These results should be interpreted in consideration of several limitations. First, we compared models of cross-disorder eff ects on the basis of the most often used goodness-of-fi t measures, but other criteria might yield diff erent results. For all four of the risk loci identifi ed in the primary meta-analysis, the selected model had a substantially better fi t than any alternative models had. However, for some loci that did not reach genome-wide signifi cance, the diff erence in fi t between our best-fi tting and alternative models was moderate (appendix pp [38] [39] [40] [41] [42] [43] [44] [45] , so more than one model could be consistent with the noted eff ects. Second, diagnostic mis classifi cation (eg, reciprocal misdiagnosis of cases of schizo phrenia and bipolar disorder) could produce spurious evidence of genetic overlap between disorders. 40 How ever, a substantial degree of misdiagnosis would be needed to account for our fi ndings of loci that aff ect all or subsets of fi ve disorders whose diagnostic criteria are fairly distinct. Third, the fi ve disorders we examined were limited to those for which large-scale GWAS datasets have been assembled by the PGC and processed through a uniform quality-control process. As further datasets become available, more comprehensive analyses of cross-disorder genetic eff ects on psychiatric illness should be pursued. Fourth, we restricted our analyses to individuals of European ancestry. Whether our fi ndings apply to other populations is unknown. Finally, GWAS designs are suited to identify common variant aspects of genetic architecture; further studies (including analyses of copynumber variants and rare mutations) will be needed to account more completely for shared genetic contributions across disorders. As in almost all GWAS of complex disorders reported so far, the eff ect sizes of genome-wide signifi cant loci are individually quite small and the variance they account for is insuffi cient for predictive or diagnostic usefulness by themselves. However, our study is the fi rst large-scale eff ort to characterise allelic eff ects across fi ve psychiatric disorders, incorporating single locus, multilocus, and path way analyses.
The identifi cation of genetic variants that confer risk of a diverse set of psychiatric disorders parallels fi ndings from other medical specialties. Most notably, GWAS 41,42 of autoimmune disorders have shown extensive overlap in genetic variants that aff ect a diverse range of diseases, including rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus, psoriasis, Crohn's disease, and type 1 diabetes. Our results provide insights into the shared causation of psychiatric dis orders (panel). In particular, alterations in calcium-channel signalling could represent a fundamental mechanism contributing to a broad vulnerability to psychopathology.
